GUIDELINES FOR CARE OF CRITICALLY ILL ADULT PATIENTS
WITH COVID-19 IN THE AMERICAS

SHORT VERSION - V2

Update, 29 July 2020

NOTE

This document is the result of a rapid guideline adaptation process. The information presented reflects published evidence as of the date of inclusion in the document. The recommendations are based on the evidence available and the quality thereof (GRADE methodology) at the time the guidelines were published. However, PAHO recognizes that there are numerous research projects under way and will periodically update these reviews and the applicable recommendations.
OBJECTIVES AND TARGET POPULATION

These clinical practice guidelines were developed in order to provide recommendations for the management of critically ill adult patients with COVID-19 treated in intensive care units (ICUs).

The target population is made up of critically ill adult patients with a suspected or confirmed diagnosis of COVID-19.

WHO defines a complicated case as one requiring respiratory support, monitoring, and management in an ICU for any patient with the following: (WHO, 2020)

- \( \text{FiO}_2/\text{PO}_2 \leq 250, \) or 2.
- Chest x-ray with bilateral patchy infiltrates
- Respiration rate \( \geq 30, \) or oxygen saturation \( \leq 90\%
- Presence of ARDS, sepsis, and/or septic shock.

SCOPE AND USERS

These clinical practice guidelines provide evidence-informed recommendations for identifying markers and mortality risk factors in critically ill patients, as well as infection control, sample collection, supportive care (respiratory and hemodynamic), pharmacological treatment, early rehabilitation, diagnostic imaging use, prevention of complications, and discharge requirements.

The recommendations are for all healthcare staff who deal with patients in emergency departments and ICUs (physicians specializing in emergency medicine, pulmonology, intensive care medicine, internal medicine, anaesthesiology, and infectious diseases; respiratory therapists, physical therapists, nurses, and pharmaceutical chemists). These guidelines are intended for use by decision-makers and government entities involved in the management of patients with COVID-19 in ICUs in the Region of the Americas.

These guidelines do not address matters related to nutrition or management of complications.

METHODOLOGY

These guidelines follow the GRADE methodology (Grading of recommendations assessment, development, and evaluation) for rapid update of the guidelines proposed by PAHO and WHO.

A multidisciplinary development group was formed by experts in critical care medicine, emergency medicine, infectious disease, anaesthesiology, pediatrics, pulmonology, epidemiology, and public health. Experts from the Pan American Health Organization were responsible for technical and methodological coordination. A prioritization process was done in order to select the questions that needed to be updated and the new questions that were included in this version of the guideline. A systematic search of the literature was completed. After the evidence selection process was conducted, the GRADE evidence profiles were created. A virtual panel of Ibero-American experts was subsequently convened to formulate recommendations, considering the context for regional implementation. All members of the development group signed conflict of interest forms, which were reviewed by the guideline coordinators. Details of the methodology are found in the long version of the guideline.
CONTINUOUS UPDATING OF GUIDELINES

These guidelines undergo a continuous process of updating evidence (live guide) in order to provide the most current recommendations for management of critically ill patients with COVID-19. Particular attention was given to potential pharmacological treatments, such as the use of antivirals, immunomodulators, convalescent plasma, and antibiotics, among others.

HOW TO USE THESE GUIDELINES

For each clinical question, a set of recommendations and good practices provides guidance for the management of critically ill patients with coronavirus disease (COVID-19). Each recommendation shows the quality of the evidence based on the GRADE system:

<table>
<thead>
<tr>
<th>Quality</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>Further research is very unlikely to change our confidence in the estimate of effect.</td>
</tr>
<tr>
<td>Moderate</td>
<td>Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.</td>
</tr>
<tr>
<td>Low</td>
<td>Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.</td>
</tr>
<tr>
<td>Very low</td>
<td>Any estimate of effect is very uncertain.</td>
</tr>
</tbody>
</table>

The recommendations also indicate the strength of the recommendation based on the GRADE system:

<table>
<thead>
<tr>
<th>Strength of recommendation</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong</td>
<td>Should be used. New evidence is unlikely to change the recommendation. RECOMMENDED</td>
</tr>
<tr>
<td>Conditional</td>
<td>Could be used. New evidence may change the recommendation. SUGGESTED</td>
</tr>
</tbody>
</table>
SUMMARY OF RECOMMENDATIONS FOR THE MANAGEMENT OF CRITICALLY ILL ADULTS PATIENTS WITH COVID-19 in THE AMERICAS

These recommendations are subject to review as new evidence becomes available.

QUESTION 1: WHAT ARE THE FACTORS AND MARKERS THAT PREDICT MORTALITY AND DISEASE PROGRESSION IN CRITICALLY ILL PATIENTS WITH COVID-19?

<table>
<thead>
<tr>
<th>No.</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>For clinical management of patients, it is recommended to consider the following risk factors for the progression of COVID-19: advanced age, hypertension, obesity, diabetes, cardiovascular disease, chronic lung disease (e.g. chronic obstructive pulmonary disease and asthma), chronic kidney disease, chronic liver disease, stroke, cancer, and disorders that can cause immunodeficiency. <strong>Strong recommendation. Quality of the evidence: moderate to low</strong></td>
</tr>
<tr>
<td>2</td>
<td>Monitoring of the following markers associated with higher mortality in critically ill patients with COVID-19 is suggested, according to availability and clinical judgment: high leukocyte count, lactate dehydrogenase, fibrinogen, cardiac troponin, C-reactive protein, creatinine, D-dimer, and ferritin. Markers related to secondary infections, such as decreased albumin levels and platelet count, should also be monitored. If possible, it is also suggested to monitor interleukin-6. <strong>Conditional recommendation. Quality of the evidence: moderate to low</strong></td>
</tr>
<tr>
<td>√</td>
<td>Critically ill patients with COVID-19 should be monitored for signs and symptoms suggesting venous or arterial thromboembolism (such as infarction), deep vein thrombosis, pulmonary embolism, or acute coronary syndrome. Proceed according to institutional protocols. <strong>Good practice statement</strong></td>
</tr>
</tbody>
</table>

QUESTION 2: WHAT TRIAGE STRATEGY SHOULD BE USED FOR CRITICALLY ILL PATIENTS WITH COVID-19?

<table>
<thead>
<tr>
<th>No.</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>√</td>
<td>Institutional protocols for triage of patients with suspected or confirmed diagnosis of COVID-19 should be implemented in order to appropriately classify patients who require management in an intensive care unit. The duration and severity of symptoms, diagnostic imaging findings (x-rays, CT scans, or lung ultrasounds, according to their availability), the origin of pulmonary infiltrates, oxygenation needs, vital organ failure, sepsis, and septic shock should be evaluated to identify critically ill patients infected with COVID-19. PAHO has an algorithm for managing patients with suspected COVID-19 infection at the first level of care and in remote areas of the Region of the Americas (<a href="https://iris.paho.org/handle/10665.2/52501">https://iris.paho.org/handle/10665.2/52501</a>). <strong>Good practice statement</strong></td>
</tr>
</tbody>
</table>
### QUESTION 3: HOW SAFE AND EFFECTIVE ARE INTERVENTIONS TO PREVENT INFECTION OF HEALTH PROFESSIONALS WHO CARE FOR PATIENTS WITH COVID-19?

<table>
<thead>
<tr>
<th>No.</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| 1   | For health care workers in contact with patients with COVID-19 who perform aerosol-generating* procedures in intensive care units (ICUs) or who work in a unit in which such procedures are performed without adequate ventilation or an independent negative pressure system, it is recommended that fitted respirator masks (N-95 respirator masks, FFP2, or equivalent) be used, in addition to other personal protective equipment (gloves, gown, and eye protection such as a face shield or safety goggles).  
  *Aerosol-generating procedures in the ICU include: endotracheal intubation, bronchoscopy, open suctioning, nebulized treatment, manual ventilation before endotracheal intubation, physical proning of the patient, disconnecting the patient from the ventilator, non-invasive positive pressure ventilation, tracheostomy, and cardiopulmonary resuscitation.*  
  **Good practice statement** |
| 2   | Aerosol-generating procedures performed on patients with COVID-19 in the ICU should be carried out in areas designated for that purpose and the best available measures for limiting contamination of other patients or health care workers should be implemented. If a negative pressure room is not available, an area with natural ventilation should be designated in all patient care areas.  
  **Good practice statement** |
| 3   | For natural ventilation, the following minimum hourly averaged ventilation rates are recommended:  
  • 160 l/s/patient (hourly average ventilation rate) for airborne precaution rooms (with a minimum of 80 l/s/patient)  
  • When patient care is undertaken in corridors during emergency or other situations, the same ventilation rate requirements for airborne precaution rooms apply.  
  • When natural ventilation alone cannot satisfy the recommended ventilation requirements, alternative ventilation systems, such as hybrid (mixed-mode) natural ventilation should be considered. If that is not enough, mechanical ventilation should be used.  
  **Good practice statement** |
| 4   | For health care workers providing care to non-mechanically ventilated COVID-19 patients in the ICU, it is suggested that surgical masks be used rather than respirator masks, in addition to other personal protective equipment.  
  **Conditional Recommendation. Quality of the evidence: low** |
| 5   | For health care workers performing non-aerosol-generating procedures on mechanically ventilated (closed-circuit) patients with COVID-19, it is recommended that surgical/medical... |
**Conditional Recommendation. Quality of the evidence: low**

**5** For health care workers performing endotracheal intubation on patients with COVID-19, it is suggested to use video-guided laryngoscopy, if available, rather than direct laryngoscopy.

**Conditional Recommendation. Quality of the evidence: low**

**V** For health care workers performing endotracheal intubation on COVID-19 patients, intubation should be performed by the health professional most experienced with airway management, following institutional protocols to minimize the number of attempts and the risk of transmission.

**Good practice statement**

**QUESTION 4: HOW SHOULD SPECIMENS BE COLLECTED FOR THE DIAGNOSIS OF COVID-19 IN PATIENTS REQUIRING INTUBATION AND MECHANICAL VENTILATION?**

<table>
<thead>
<tr>
<th>No.</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| **6** | For adult patients with suspicion of COVID-19 that need to be intubated and mechanically ventilated, it is suggested:  
- For diagnostic testing, samples should be obtained from the lower respiratory tracts (at the time of intubating or as close as possible), rather than obtaining samples from the upper respiratory tract (nasopharyngeal or oropharyngeal samples).  
- For lower respiratory samples, endotracheal aspirates should be obtained, rather than bronchial wash or bronchoalveolar lavage samples.  

**Conditional Recommendation. Quality of the evidence: low** |
| **V** | Rapid collection and testing of specimens from patients with suspected COVID-19 should be a priority and should be carried out by experts in accordance with biosafety recommendations. It is recommended that the laboratory procedure for endotracheal aspirates be institutionally validated in order to avoid false negatives.  
   Extensive testing should be conducted in accordance with the need to confirm SARS-CoV-2 and possible coinfections. Institutional guidelines for obtaining informed consent for specimen collection, testing, and future research should be followed.  

**Good practice statement** |
| **V** | Tests should be performed for differential diagnosis with other pathologies (e.g. influenza, malaria, dengue) according to clinical features and local epidemiology.  

**Good practice statement** |
**QUESTION 5: WHAT ARE THE SAFETY AND EFFICACY OF RESPIRATORY SUPPORT INTERVENTIONS FOR CRITICALLY ILL PATIENTS WITH COVID-19 IN INTENSIVE CARE UNITS?**

<table>
<thead>
<tr>
<th>No.</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| 7   | In adult patients with COVID-19 with acute respiratory distress syndrome (ARDS) and respiratory failure, hypoxemia, or shock (who are not intubated or receiving mechanical ventilation), we recommend that supplementary oxygen be given immediately until SpO2 ≥ 94%.  
**Strong Recommendation**  
**Quality of the evidence: moderate** |
| 8   | For adult patients with COVID-19 and acute hypoxemic respiratory failure who are receiving oxygen, we recommend that SpO2 be maintained at no higher than 96%.  
**Strong Recommendation**  
**Quality of the evidence: moderate** |
| 9   | In adult patients with COVID-19 and acute hypoxemic respiratory failure in need of supplemental oxygen, non-invasive ventilation with an interface (facial masks, helmets) or high-flow nasal oxygen are suggested, according to availability, in order to reduce mortality and likelihood of intubation.  
**Conditional Recommendation. Quality of the evidence: very low** |
|     | Patients with respiratory distress who have progressive acute hypoxemic respiratory failure and do not respond to oxygen therapy via mask (flow rate of 10-15 L/min corresponding to minimum flow to maintain the inflation bag; with FiO2 between 0.60-0.95) should be provided with non-invasive mechanical ventilation or high-flow nasal cannulae. In the absence of these methods, invasive mechanical ventilation should be used.  
**Good practice statement** |
|     | Oxygen therapy with high-flow nasal cannulae (HFNC) and non-invasive ventilation (NIMV) should be used in units where patients with suspected or confirmed COVID-19 are hospitalized only if the area is adequately ventilated or has a negative pressure system, and if all staff in the area use correct airborne precautions. If this is not possible, it is preferable to use mechanical ventilation with orotracheal intubation.  
**Good practice statement** |
| 10  | In mechanically ventilated adults with COVID-19 and ARDS, it is recommended to use low tidal volume ventilation (4–8 mL/kg of predicted body weight) and to maintain *plateau* pressures of <30 cm H₂O. Deep sedation is required for patients to achieve the proposed goals.  
**Strong Recommendation**  
**Quality of the evidence: moderate** |
| 11  | For mechanically ventilated adult patients with COVID-19 and ARDS, it is suggested a conservative strategy of positive end-expiratory pressure (PEEP) to prevent barotrauma. *(If using a higher PEEP strategy, personnel should monitor patients who do not respond to higher PEEP levels for barotrauma).*  
**Conditional Recommendation. Quality of the evidence: low** |
| 12 | For mechanically ventilated adults with COVID-19 and ARDS, using a conservative fluid strategy is recommended, as opposed to a liberal fluid strategy.  
**Strong Recommendation** Quality of the evidence: low |
| 13 | For mechanically ventilated adults with COVID-19 and moderate to severe ARDS, prone ventilation for 12 to 16 hours is suggested, as opposed to non-prone ventilation. This will require sufficient human resources and expertise to carry out the procedure safely and in a standardized manner. Pregnant women may benefit from being placed in a lateral decubitus position.  
**Conditional Recommendation. Quality of the evidence: moderate** |
| 14 | For mechanically ventilated adults with COVID-19 and moderate to severe ARDS:  
- Intermittent boluses of neuromuscular blocking agents (NMBA) are suggested, as opposed to continuous NMBA infusion, in order to facilitate protective lung ventilation.  
- In the event of persistent ventilator dyssynchrony, there may be a need for ongoing deep sedation, prone ventilation, or persistently high plateau pressures, using a continuous NMBA infusion for up to 48 hours.  
**Conditional Recommendation. Quality of the evidence: low** |
| 15 | In mechanically ventilated adults with COVID-19 and ARDS, the use of inhaled nitric oxide is not recommended.  
**Strong Recommendation Quality of the evidence: low** |
| 16 | For mechanically ventilated adults with COVID-19 and refractory hypoxemia despite optimized ventilation, the use of recruitment maneuvers is suggested; incremental PEEP (gradual increases in PEEP) is not recommended.  
**Strong Recommendation Quality of the evidence: moderate** |
| 17 | In adult patients with COVID-19 with or without ARDS or acute hypoxemic respiratory failure in need of supplemental oxygen, prone position is recommended for at least 3 hours. It should not be maintained if the patient reports discomfort or oxygenation does not improve. This is evaluated within the first 15 minutes of placing the patient in prone position.  
**Conditional Recommendation. Quality of the evidence: very low** |
| 18 | In adult patients who produce or retain secretions and/or have a weak cough, it is suggested to use secretion removal techniques (e.g. postural drainage or respiratory flow acceleration maneuvers) to promote airway cleanliness and improve the safety of health professionals. Mechanical devices should not be used.  
**Conditional Recommendation. Quality of the evidence: very low** |
| v | Disconnecting the patient from the ventilator is not recommended, given the loss of PEEP, the risk of atelectasis, and the increased risk of infection for healthcare professionals caring for patients.  
**Conditional Recommendation. Quality of the evidence: very low** |
Good practice statement

Extracorporeal membrane oxygenation (ECMO), if available, or referral of patients to an ECMO center, is suggested in the following cases of critically ill patients with COVID-19 and severe ARDS:
Mechanically ventilated patients with COVID-19 and refractory hypoxemia who do not respond to recommended therapeutic alternatives (ventilation optimization, use of rescue therapies, and prone ventilation)
ECMO should not be used for the following patients:
Patients with terminal disease or central nervous system damage, patients with do-not-resuscitate orders or who refuse ECMO
Patients with significant comorbidities
Patients over 65 years of age
Patients who have been on mechanical ventilation for more than 7 days

Conditional recommendation. Quality of the evidence: very low

QUESTION 6: WHAT ARE THE EFFICACY AND SAFETY OF HEMODYNAMIC SUPPORT INTERVENTIONS FOR CRITICALLY ILL PATIENTS WITH COVID-19 IN THE INTENSIVE CARE UNIT?

<table>
<thead>
<tr>
<th>No.</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>For the acute resuscitation of adults with COVID-19 and shock, a conservative fluid administration strategy is suggested, rather than a liberal strategy.</td>
</tr>
<tr>
<td>21</td>
<td>In adults with COVID-19 and shock, various dynamic parameters should be used to assess fluid responsiveness. The following may be useful: stroke volume variation, pulse pressure variation, skin temperature, capillary refilling time, and/or serum lactate measurement.</td>
</tr>
<tr>
<td>22</td>
<td>For the acute resuscitation of adults with COVID-19 and shock, the administration of 250–500 ml of a crystalloid solution is recommended, rather than a colloid solution. Crystalloid solutions include normal saline solution and Ringer’s lactate.</td>
</tr>
<tr>
<td>23</td>
<td>For the acute resuscitation of adults with COVID-19 and shock, buffered/balanced crystalloids should be used, if available, rather than unbalanced crystalloids. Balanced crystalloid solutions include lactate, Ringer’s, or other multi-electrolytic solutions.</td>
</tr>
<tr>
<td>24</td>
<td>Administration of fluids can lead to volume overload including respiratory failure, particularly with ARDS. If there is no response to fluid loading or signs of volume overload appear (jugular venous distension, crackles on lung auscultation, pulmonary oedema on imaging, or hepatomegaly), reduce or discontinue fluid administration.</td>
</tr>
<tr>
<td>25</td>
<td>For the acute resuscitation of adults with COVID-19 and shock, we recommend against the use of hydroxyethyl starches, gelatins, or dextrans</td>
</tr>
</tbody>
</table>
For the acute resuscitation of adults with COVID-19 and shock, we suggest against the routine use of albumin.

Conditional recommendation. Quality of the evidence: low

QUESTION 7: WHAT ARE THE SAFETY AND EFFICACY OF VASOPRESSORS AND CORTICOSTEROIDS FOR THE TREATMENT OF CRITICALLY ILL PATIENTS WITH COVID-19 IN SHOCK?

<table>
<thead>
<tr>
<th>No.</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| 26  | For adults with COVID-19 and shock, norepinephrine should be used as the first-line vasoactive agent, rather than other agents.  
Conditional recommendation. Quality of the evidence: low |
| 27  | For adults with COVID-19 and shock, if norepinephrine is not available, we suggest either vasopressin or epinephrine be used as the first-line vasoactive agent, rather than other vasoactive agents.  
Conditional recommendation. Quality of the evidence: low |
| 28  | For adults with COVID-19 and shock, we recommend against the administration of dopamine, given its low safety profile compared with the other vasopressors.  
Strong recommendation Quality of the evidence: moderate |
| 29  | For adults with COVID-19 and shock, titrating vasoactive agents should be used to achieve a mean arterial pressure (MAP) of 60–65 mmHg, rather than higher MAP targets.  
Conditional recommendation. Quality of the evidence: low |
| 30  | For adults with COVID-19 and shock, we suggest adding vasopressin as a second-line agent if the target mean arterial pressure (MAP) cannot be achieved by norepinephrine alone.  
Conditional recommendation. Quality of the evidence: moderate |
| 31  | For adults with COVID-19 and shock with evidence of cardiac dysfunction and persistent hypoperfusion despite fluid resuscitation and norepinephrine, we suggest adding dobutamine (with prior echocardiography), rather than increasing the norepinephrine dose.  
Conditional recommendation. Quality of the evidence: very low |
| 32  | For adults with COVID-19 and shock who require the addition of a second vasopressor, low-dose corticosteroid therapy is suggested.  
Conditional recommendation. Quality of the evidence: low |
|     | Vasopressors should be administered when shock persists during or after fluid resuscitation to achieve target MAP and improve perfusion markers. If central venous catheters (CVC) are not available, vasopressors can be administered through a peripheral intravenous catheter (for a short time, at low doses), using a large vein and closely monitoring for signs of extravasation and tissue necrosis, until a CVC can be placed. Whenever possible, a CVC should be inserted in the first 24–48 hours of vasopressor use.  
Good practice statement |
**QUESTION 8: HOW USEFUL IS DIAGNOSTIC IMAGING IN GUIDING TREATMENT OF CRITICALLY ILL PATIENTS WITH COVID-19?**

<table>
<thead>
<tr>
<th>No.</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>33</td>
<td>For hospitalized patients with severe symptoms (high risk of disease progression, unresponsive to supplemental oxygen treatment, or clinical suspicion of pulmonary fibrosis, pulmonary thromboembolism, or thrombosis), diagnostic imaging is suggested to guide treatment, in addition to clinical and laboratory evaluation. Conditional recommendation. Quality of the evidence: very low</td>
</tr>
<tr>
<td>✓</td>
<td>The type of diagnosis should be selected based on availability, location of the deterioration, type of patient (mechanical ventilation), and preferential diagnosis. Chest CT scans or x-rays, and lung ultrasounds are preferred. Good practice statement</td>
</tr>
</tbody>
</table>

**QUESTION 9: WHAT ARE THE SAFETY AND EFFICACY OF PHARMACOLOGICAL INTERVENTIONS FOR THE TREATMENT OF CRITICALLY ILL PATIENTS WITH COVID-19 IN INTENSIVE CARE UNITS?**

<table>
<thead>
<tr>
<th>No.</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>34</td>
<td>The following drugs are not recommended for treatment of critically ill patients with COVID-19 outside of clinical trials.</td>
</tr>
<tr>
<td></td>
<td>• Antiparasitic agents</td>
</tr>
<tr>
<td></td>
<td>o Chloroquine and hydroxychloroquine with or without azithromycin</td>
</tr>
<tr>
<td></td>
<td>o Nitazoxanide</td>
</tr>
<tr>
<td></td>
<td>o Ivermectin</td>
</tr>
<tr>
<td></td>
<td>• Antivirals, including, but not limited to:</td>
</tr>
<tr>
<td></td>
<td>o Lopinavir/ritonavir</td>
</tr>
<tr>
<td></td>
<td>o Remdesivir</td>
</tr>
<tr>
<td></td>
<td>o Favipiravir</td>
</tr>
<tr>
<td></td>
<td>o Oseltamivir</td>
</tr>
<tr>
<td></td>
<td>o Zanamivir</td>
</tr>
<tr>
<td></td>
<td>• Immunomodulators, including, but not limited to:</td>
</tr>
<tr>
<td></td>
<td>o Tocilizumab</td>
</tr>
<tr>
<td></td>
<td>o Interferon-β-1a</td>
</tr>
<tr>
<td></td>
<td>o Interferon-α</td>
</tr>
<tr>
<td></td>
<td>o Meplazumab</td>
</tr>
<tr>
<td></td>
<td>o Immunoglobulin</td>
</tr>
<tr>
<td></td>
<td>• Convalescent plasma</td>
</tr>
<tr>
<td></td>
<td>• Colchicine</td>
</tr>
<tr>
<td></td>
<td>• N-Acetyl Cysteine</td>
</tr>
<tr>
<td></td>
<td>Conditional recommendation. Quality of the evidence: low</td>
</tr>
<tr>
<td>No.</td>
<td>Recommendation</td>
</tr>
<tr>
<td>-----</td>
<td>----------------</td>
</tr>
<tr>
<td>35</td>
<td>For critically ill patients with COVID 19 receiving supplemental oxygen or ventilation, we recommended low-dose of corticosteroids to reduce mortality and progression to invasive mechanical ventilation. <strong>Strong recommendation. Quality of the evidence: moderate</strong></td>
</tr>
<tr>
<td>36</td>
<td>In mechanically ventilated patients with COVID-19 and respiratory failure, empiric antimicrobials/antibacterial agents should be used for 5 to 7 days, following institutional protocols and considering the clinical diagnosis (for example, community-acquired pneumonia, sepsis, or suspected associated bacterial infection) and local data on bacterial resistance. <strong>Conditional recommendation. Quality of the evidence: low</strong></td>
</tr>
<tr>
<td>37</td>
<td>The administration of antibiotics should be initiated within an hour of assessing the patient. Antibiotic therapy should be deescalated on the basis of microbiological results and clinical judgment. <strong>Good practice statement</strong></td>
</tr>
<tr>
<td>38</td>
<td>In adults with COVID-19 who develop fever, we suggest that drugs should be used for temperature control. The choice of drug will depend on each patient’s comorbidities. <strong>Conditional recommendation. Quality of the evidence: low</strong></td>
</tr>
<tr>
<td>39</td>
<td>For critically ill patients with COVID 19, we recommend against the administration of NSAIDs. <strong>Conditional recommendation. Quality of the evidence: very low</strong></td>
</tr>
</tbody>
</table>

**QUESTION 10: WHAT ARE THE GUIDELINES FOR PREVENTION OF COMPLICATIONS ASSOCIATED WITH THE TREATMENT OF CRITICALLY ILL PATIENTS WITH COVID-19?**

<table>
<thead>
<tr>
<th>No.</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>39</td>
<td>In critically ill patients without contraindication to anticoagulants, pharmacological prophylaxis, such as low molecular weight heparin (LMWH), is recommended, in accordance with local and international standards, to prevent venous thromboembolism. For patients with contraindications, it is suggested the use of mechanical prophylaxis (intermittent pneumatic compression devices). <strong>Strong recommendation. Quality of the evidence: very low</strong></td>
</tr>
<tr>
<td>39</td>
<td>Patients at high risk of thromboembolism should be identified according to the following markers: high levels of C-reactive protein, fibrinogen, and D-dimer. Critically ill patients with COVID-19 and high risk of thromboembolism, without kidney complications and at low risk of bleeding, should receive 1 mg/kg of enoxaparin per day. <strong>Strong recommendation. Quality of the evidence: very low</strong></td>
</tr>
</tbody>
</table>
for at least 7 days. Side effects and markers should be tracked if decreasing enoxaparin to 40 mg.

**Good practice statement**

The use of proton pump inhibitors is suggested in selected patients with continued vasopressor use, at prophylactic doses for short periods of time, to prevent bleeding from stress ulcers. Patients should be monitored for risk of nosocomial infections.

**Conditional recommendation. Quality of the evidence: very low**

Drug interactions and side effects of administered medications that may affect COVID-19 symptoms (including effects on respiratory, cardiac, neurological, mental, and immune functions) should be carefully considered.

**Good practice statement**

The following interventions are recommended to prevent complications associated with the management of critically ill patients with COVID-19:

**Reduce the incidence of ventilator-associated pneumonia**

- Use an institutional protocol for ventilator weaning that includes daily assessment.
- Oral intubation is preferable to nasal intubation in adolescents and adults.
- Keep the patient in a semi-recumbent position (head elevation of 30°–45°).
- Use a closed suctioning system; periodically drain and discard condensate in tubing.
- Use a new ventilator circuit for each patient; once the patient is ventilated, change the circuit if soiled or damaged, but not routinely.
- Change the heat moisture exchanger when it malfunctions, when soiled, or every 5–7 days.
- Reduce the incidence of blood infections associated with intravenous devices

- Use a checklist as a reminder of each step needed for sterile insertion and as a daily reminder to remove the intravenous device if no longer needed.

**Reduce the incidence of pressure ulcers**

- Turn the patient on his/her side every two hours.
- Actively mobilize the ill patient when safe to do so.

**Reduce the incidence of stress ulcers and gastrointestinal bleeding**

- Give early enteral nutrition (within 24–48 hours of admission).

**Reduce the risk of delirium**

- Use protocols for prevention, continuous monitoring, and management of acute delirium
- Use nonpharmacological interventions to prevent and treat delirium (reorientation, schedules, clocks, natural lighting, reduce ambient noise, facilitate sleep, avoid drugs with deliriogenic potential, etc.)
- Use pharmacological interventions to treat delirium.

**Good practice statement**
**QUESTION 11: WHAT IS THE EFFICACY AND SAFETY OF EARLY REHABILITATION FOR PATIENTS WITH COVID-19 IN INTENSIVE CARE UNITS?**

<table>
<thead>
<tr>
<th>No.</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>41</td>
<td>For patients hospitalized in the ICU with COVID-19, early rehabilitation is suggested to reduce weakness acquired in the ICU.</td>
</tr>
<tr>
<td></td>
<td>Conditional recommendation. Quality of the evidence: very low</td>
</tr>
<tr>
<td>v</td>
<td>The type of early rehabilitation depends on the patient, type of ventilation, whether the patient is sedated, and the resources available in the facility.</td>
</tr>
<tr>
<td></td>
<td>Good practice statement</td>
</tr>
</tbody>
</table>

**QUESTION 12: WHAT ARE THE REQUIREMENTS FOR DISCHARGE OF COVID-19 PATIENTS FROM THE INTENSIVE CARE UNIT?**

<table>
<thead>
<tr>
<th>No.</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>42</td>
<td>For patients hospitalized in the ICU with COVID-19 whose symptoms have improved, a clinical, laboratory evaluation, it is suggested to be performed to verify that no respiratory, renal, or hemodynamic support is required, before making the decision to discharge patients from the unit.</td>
</tr>
<tr>
<td></td>
<td>Conditional recommendation. Quality of the evidence: very low</td>
</tr>
<tr>
<td>v</td>
<td>For patients receiving oral anticoagulants prior to ICU admission, it is recommended to make a risk stratification of developing venous thromboembolism after discharge and to consider extending prophylaxis using standard doses.</td>
</tr>
<tr>
<td></td>
<td>Strong recommendation. Quality of the evidence: very low</td>
</tr>
<tr>
<td>43</td>
<td>For patients who have been discharged from the intensive care unit, it is recommended to evaluate swallowing, mobility, delirium, cognitive decline, and mental health. Based on the evaluation, rehabilitation and follow-up requirements are determined.</td>
</tr>
<tr>
<td></td>
<td>Good practice statement</td>
</tr>
<tr>
<td>v</td>
<td>Patients who meet the ICU's discharge requirements, it is suggested to leave with an exit plan that includes a summary of the diagnosis upon discharge, medications, and a care plan. The patient and their family should also receive information about their care.</td>
</tr>
<tr>
<td></td>
<td>Conditional recommendation. Quality of the evidence: very low</td>
</tr>
<tr>
<td>v</td>
<td>A rehabilitation program (from discharge to long term) should be developed after discharge from the intensive care unit; with referral to specialized rehabilitation services or centers designed to care for patients with COVID-19 who remain infectious. Consider performing scheduled activities virtually.</td>
</tr>
<tr>
<td></td>
<td>Good practice statement</td>
</tr>
<tr>
<td>v</td>
<td>Rehabilitation programs should be implemented by multidisciplinary teams and should be geared around patient needs and goals, including physical therapy; education and advice</td>
</tr>
</tbody>
</table>
on self-care strategies; breathing techniques; support for caregivers; support groups, stress management, and home modifications.

**Good practice statement**
USE OF PROTECTIVE EQUIPMENT

- Requirements and technical specifications of personal protective equipment (PPE) for the novel coronavirus (2019-ncov) in healthcare settings
- Technical specifications of medical devices for the case management of COVID-19 in healthcare settings
- Interim laboratory biosafety guidelines for the handling and transport of samples associated with the novel coronavirus 2019 (2019-nCoV)
- Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected
- Natural ventilation for infection control in healthcare settings

DIAGNOSIS OF COVID-19

- Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV in humans
- Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases
- Guidance for laboratories shipping specimens to WHO reference laboratories that provide confirmatory testing for COVID-19 virus
TREATMENT

- Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected
- Home care for patients with suspected novel coronavirus (2019-nCoV) infection presenting with mild symptoms and management of contacts
- COVID-19: Chloroquine and hydroxychloroquine research

GLOBAL MONITORING OF COVID-19

- Global Surveillance for human infection with coronavirus disease (COVID-19)
- Revised case report form for Confirmed Novel Coronavirus COVID-19 (report to WHO within 48 hours of case identification)

DISCHARGE OF RECOVERED PATIENTS

- Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected
- Novel coronavirus (SARS-CoV-2) Discharge criteria for confirmed COVID-19 cases – When is it safe to discharge COVID-19 cases from the hospital or end home isolation?

CONSIDERATIONS IN INVESTIGATION AND IN HEALTH SERVICES

- Considerations in the investigation of cases and clusters of COVID-19
- Operational considerations for case management of COVID-19 in health facility and community
**COVID-19**

- Reorganization and Progressive Expansion of Health Services for the Response to the COVID-19 Pandemic
- Severe Acute Respiratory Infections Treatment Centre

**DEAD BODY MANAGEMENT**

- Dead body management in the context of the novel coronavirus (COVID-19)
The patient arrives in the health center with Acute Respiratory Disease

Offer surgical mask to the patient if he or she tolerates it

Does the patient present signs and symptoms of COVID-19 (A)?

Yes

Check vital signs and oxygen saturation
Are there signs of severe illness?
(See box B - Severe Illness)

Severe illness (See box B): respiratory distress, ARDS, sepsis, threat to life, organ failure.

Admit patient to Intensive Care Unit (ICU) if possible
Initiate Acute Respiratory Infection protocol
Manage and mitigate potential complications.

Moderate illness
Pneumonia with oxygen saturation of >= 90 with respiratory infection or
Mild (not pneumonia) + risk factors for deterioration (according to clinical judgement)

Admit patient to isolation room
Monitor signs and symptoms
Collect laboratories and examinations
Consider supplemental oxygen therapy
Reasses according to protocols

Some risk factors
Continue with the next step

No risk factors

Conduct basic management and return to see if clinical deterioration is present (Box E)

Clinical presentation

Routine evaluation

Immediate physical examination

Physical examination and clinical history, obtain laboratories and imaging (chest x-ray, CAT, ultrasound, or ultrasonogram)

Review risk of severe illness in boxes: (Box C - Factors ) (Box D - Laboratories)

NO

Follow clinical evaluation according to local protocols, including evaluation for other respiratory infections

Yes

Box A: Common COVID-19 symptoms
Fever
Cough + Sputum
Breathlessness
Muscle pain (myalgia)
Fatigue
Nausea/Vomiting
Cold
Diarrhea
Headache
Sore throat
Vasculitic rash

Box B: Signs of severe illness
Respiratory rate > 30
Pulse > 100
Hypotension
Arrhythmia
Evidence of dyspnea (muscular, cervical, or intercostal retraction, nostril flaring, cyanosis, oxygen saturation < 94%, or based on clinical

Box C: Risk Factors
Atherosclerosis
Cancer
Diabetes
Males
Cardiovascular disease
Liver disease
Neurological disease
Pulmonary disease
Kidney disease
Hypertension
Immunodeficiency for any reason
Obesity
People over 60 years of age

Box D: routine laboratory tests according to availability
Respiratory specimens for viral assessment of COVID-19
Liver function
Blood count
Other laboratory tests based on local epidemiology (influenza, other respiratory infections, dengue, malaria)
Urine analysis

Additional laboratory tests according to availability
Procalcitonin
CPK
D-dimer and fibrinogen
C-reactive protein

Diagnostic imaging according to availability
Chest x-ray
Chest CT scan

Box E: Signs of deterioration
Increase in difficulty breathing
Drop in blood pressure
Blue coloration in lips and face
Confusion or lack of ability to rise
Increased weakness
Reduction of oxygen saturation to less than 90%
Persistent chest pain
Reddening or inflammation of the limbs
Dizziness
Loss of consciousness
Respiratory rate higher than 20
Proposed algorithm for treatment of critically ill patients with septic shock.

**Initial Management**

- **Patient with clinical criteria for septic shock.**
  - Suspected or documented infection
  - Arterial hypotension (typically SBP ≤ 90 mm Hg or MAP ≤ 65 mm Hg)
  - Evidence of tissue hypoperfusion.

- **Begin fluid bolus therapy**
  - IV fluids, 250–500 ml over 15–30 minutes;
  - Hold if fluid replete or overload.

Assess clinical severity
- Measure lactate level immediately
- Obtain prognostic markers according to availability

Rapid clinical reassessment within 15–30 minutes.

- **Is shock still present?**
  - **NO**
  - Hold if fluid replete
  - Overloaded

- **YES**
  - Perform a clinical examination (assess mental status, peripheral perfusion, urine output)
  - Reassess if fluid replete or overload
  - Prompt clinical reassessment within hours
    - **Repeat** lactate level
    - **Performs** a clinical examination (assess mental status, peripheral perfusion, urine output)
    - **Reassess** if fluid replete or overload

Consider diagnostic imaging
- **Does the patient have LV or RV dysfunction?**
  - **NO**
  - Advanced diagnostics
    - Consider formal ECHO, repeat ECG, troponin levels.
  - **YES**

Consider vasopressors
- **Start vasopressors**
  - Norepinephrine as first-line agent.
  - Prompt clinical reassessment within hours
  - **Perform** a clinical examination (assess mental status, peripheral perfusion, urine output)
  - Reassess if fluid replete or overload

- **Fluid replete or overload?**
  - **YES**
    - Consider intravenous fluids to replace ongoing losses.

Persistent shock?
- **YES**
  - Treatment of persistent shock
    - Reassess etiology of shock and control of infectious source.
    - Consider vasopressin, 0.04U/min, if high norepinephrine dose.
    - If norepinephrine is not available, use ephinephrine.
    - Consider corticosteroids if shock is refractory.
    - Wean off tolerated vasopressors once perfusion targets are met.

- **NO**

Persistent shock?
- **YES**
  - De-escalate therapy for septic shock and consider fluid volume removal when safe
  - **NO**

Address suspected infection
- Immediately obtain bodily fluid cultures
- Begin antibiotics for 5 to 7 days according to institutional protocols
- Consider diagnostic imaging
- Institute prompt infectious source control

**Source:** Seymour and Rosengart (2015).
**Risk Factors**
- Arteriosclerosis
- Cancer
- Diabetes
- Male
- Cardiovascular disease
- Liver disease
- Neurological disease
- Lung disease
- Kidney disease
- Hypertension
- Immunodeficiency due to any cause
- Obesity
- Over 60 years old

**Routine laboratory tests, if available**
- Respiratory specimens for COVID-19 viral test
- Liver function
- Complete blood count
- Other laboratory tests depending on local epidemiology (e.g., influenza, other respiratory infections, dengue, malaria)
- Urinalysis

**Additional laboratory tests, if available**
- CPK
- D-dimer and fibrinogen
- C-reactive protein

**Diagnostic imaging, if available**
- Chest X-ray
- Chest CT scan

---

**FLOWCHART FOR THE MANAGEMENT OF COVID-19 INFECTION AT THE FIRST LEVEL OF CARE AND IN REMOTE AREAS**

Surveillance of Suspected COVID-19 Patients

- Fever higher than 38°C with dry cough and/or difficulty breathing?
- Shortness of breath, joint or muscle pain, loss of sense of smell/taste, weakness, diarrhea, abdominal pain, persistent diarrhea, headache, chills, fatigue, and/or sore throat?
- Patient has acute respiratory illness with fever and difficulty breathing in the absence of another diagnosis that would account for the clinical presentation?

**High**

- Isolate patient at home or in a facility designated for suspected COVID-19 cases.
- If patient develops fever or pain, administer acetaminophen (500 mg every 6 to 8 hours up to 4 g a day).
- Refer to second level of care.

**Low or Moderate**

- Evaluate risk for thromboembolism (respiratory rate over 20, increased levels of C-reactive protein, D-dimer, and fibrinogen)
- Administer acetaminophen 500 mg every 6 to 8 hours (maximum 4 g per day).
- Do not administer antibiotics unless a bacterial infection is suspected.

**No risk factors* (suspected mild COVID-19)**

- Isolate patient at home or in a facility designated for treating suspected COVID-19 cases.
- Monitor vital signs and watch for emergency signs.
- Consider administering oxygen support.
- If patient presents emergency signs (SpO2 <90% or respiratory rate >24) or pneumonia (fever, cough, shortness of breath, rapid breathing), Call for consultation and initiate referral to second level of care.

**More than one risk factor**

- Isolate patient in a facility designated for treating suspected COVID-19 cases.
- Monitor vital signs and watch for emergency signs.
- Consider administering oxygen support.
- If patient’s respiratory distress increases or SpO2 remains lower than 90%:
  - Use oxygen mask.
  - Increase oxygen flow to 6 to 10 L/min.
  - Evaluate response and check for signs of deterioration every 4 hours***

**All patients regardless of risk factors**

- Administer intravenous fluids conservatively.
- Evaluate response and watch for emergency signs.
- When administering oxygen, estimate FiO2 as follows: 2,4 L/min (FiO2 0.28 - 0.36); 5 L/min (FiO2 0.40 - 0.44); 6, 10 L/min (FiO2 0.44 to 0.60); 10, 15 L/min (FiO2 0.63 - 0.95).
- If patient stabilizes (SpO2 >90%, vital signs), continue management, evaluate response, and watch for any signs of deterioration ***

**Low**

- Refer to second level of care.

---

**Emergency Signs**

- Loss of consciousness
- Dizziness
- Persistent chest pain
- Increased weakness
- Confusion or inability to sit up
- Bluish lips and face
- Drop in blood pressure
- Increased difficulty breathing
- Oxygen saturation lower than 90%
- Persistent chest pain
- Reddening or inflammation of limbs
- Dizziness
- Loss of consciousness
- Respiratory rate more than 20
ACKNOWLEDGEMENTS

PAHO wishes to thank the members of the development group who participated in the rapid development of these guidelines.

The PAHO technical and methodological coordinating group consists of Ludovic Reveiz, Advisor in the Department of Evidence and Intelligence for Action in Health and the Incident Management System team for PAHO’s COVID-19 response; Joao Toledo, Advisor in the Health Emergencies Department and the Incident Management System team for PAHO’s COVID-19 response; Marcela Torres and Paul Alexander Elías, consultants in the Department of Evidence and Intelligence for Action in Health and the Incident Management System team for PAHO’s COVID-19 response; Jairo Méndez and Luis de la Fuente, Advisors in the Health Emergencies Department and the Incident Management System team for PAHO’s COVID-19 response; and José Luis Castro, Alexandre Lemgruber, Francisco Caccavo, and Mauricio Beltrán, Advisors in PAHO’s Health Systems and Services Department.

The expert panel consisted of: Dr. Marcio Borges Sa, National Coordinator of Código Sepsis in Spain, Hospital Son Llatzer, Sepsis Group of Balearic Islands Health Research Institute (IDISBA), Pan American and Iberian Federation of Intensive and Critical Care Medicine; Dr. Thiago Costa Lisboa, Hospital de Clínicas, Porto Alegre, Federal University of Rio Grande do Sul, La Salle University and Research Institute, Hospital do Coração (Heart Hospital) of Brazil; Dr. Fabián Jaimes, Professor in the Department of Internal Medicine of the Medical School of the University of Antioquia, Coordinating Editor of IATREIA (medical journal of the University of Antioquia), Colombia; Dr. Luis Antonio Gorordo Delsol, Adult Intensive Care Unit, Juárez Hospital, Mexico, Director of Fundación Sepsis of Mexico; Dr. Sonia Restrepo, Pediatric Pulmonologist, Professor at the Medical School of the National University of Colombia, Fundación la Misericordia Hospital and San Ignacio University Hospital, Colombia; Dr. Angel Rodriguez, PAHO; Dr. Leonardo Salazar, Coordinator, Education Committee, Extracorporeal Life Support Organization (ELSO) Latin America, Medical Director, ECMO and VAD Program, Fundación Cardiovascular, Colombia; Dr. Ojino Sosa, Specialist in Internal and Critical Care Medicine, Director of Integration of Clinical Practice Guidelines, National Center for Technological Excellence in Health (CENETEC), attending physician at the Médica Sur Hospital, Mexico; Dr. Sebastián Ugarte Ubierno, Chief, Center for Critical Patients, Indisa Clinic, Andrés Bello University, Chile, Former President, Pan American and Iberian Federation of Intensive and Critical Care Medicine (FEPIMCTI), Council, World Federation of Societies of Intensive and Critical Care Medicine; and Dr. Ho Yeh Li, Coordinator, ICU-DMIP, Hospital de Clínicas, Porto Alegre, Federal University of Rio Grande do Sul, Brazil.

PAHO/IMS/EIH/COVID-19/20-0013

© Pan American Health Organization, 2020. Some rights reserved. This work is available under license CC BY-NC-SA 3.0 IGO.